Methylation of the MGMT promoter has been observed in approximately 50% of grade 4 gliomas, commonly referred to as glioblastoma multiforme (GBM).14 MGMT status holds strong prognostic value and potential predictive information on the benefit of alkylating chemotherapy.15 This evidence concerns the gene MGMT and glioblastoma.